# PGLYRP1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PGLYRP1 is a secreted pattern recognition receptor that directly binds bacterial peptidoglycan (PGN), acting as a bactericidal and bacteriostatic agent by disrupting bacterial membranes and inducing oxidative stress.
- Structurally, PGLYRP1 possesses a peptidoglycan-binding domain with an amidase-like architecture, though critical active-site substitutions render it catalytically inactive as an amidase, preserving its PGN-binding function.
- Clinically, *PGLYRP1* polymorphisms are associated with inflammatory bowel disease (IBD) and psoriasis, and the protein plays a dualistic role in cancer, potentially promoting tumor surveillance via HSP70 interaction or tumor progression by suppressing NK cell activity.
- Pathogenic variants, such as p.Arg96Trp and p.Arg141Cys, lead to loss of PGN binding and impaired function, respectively, resulting in increased susceptibility to recurrent bacterial infections and immunodeficiency.
- Bacterial pathogens like *Staphylococcus aureus* and *Listeria monocytogenes* have evolved evasion mechanisms, including proteolytic cleavage of PGLYRP1 by aureolysin or direct inhibition by listeriolysin O, to counteract its antimicrobial effects.
- Therapeutic strategies under investigation include recombinant PGLYRP1-HSP70 complexes for cancer treatment and PGLYRP1-neutralizing antibodies for inflammatory conditions, highlighting its complex role as a potential drug target.

---

## Executive Summary & Key Metadata

Peptidoglycan Recognition Protein 1 (PGLYRP1), also known as Tag7 or PGRP-S, is a pattern recognition receptor (PRR) of the innate immune system that directly binds bacterial peptidoglycan (PGN). Unlike many other PRRs that initiate signaling cascades, PGLYRP1 functions primarily as a bactericidal and bacteriostatic agent, and it has emerged as a critical regulator of inflammatory responses, tumor surveillance, and host–pathogen interactions. The protein is a secreted, ~22 kDa molecule that is constitutively expressed in neutrophil granules, eosinophils, and certain epithelial barriers. Its unique structural fold—a peptidoglycan-binding domain with a zinc-dependent amidase-like architecture—underpins its dual roles in direct bacterial killing and modulation of sterile inflammation.

The clinical relevance of PGLYRP1 extends beyond infection control. Genome-wide association studies (GWAS) have linked *PGLYRP1* polymorphisms to inflammatory bowel disease (IBD), psoriasis, and altered susceptibility to tuberculosis. In oncology, PGLYRP1 is overexpressed in several solid tumors and has been implicated in immune evasion via its interaction with the heat shock protein HSP70, leading to the formation of a cytotoxic complex that targets tumor cells. Conversely, PGLYRP1 can promote tumor progression in certain microenvironments by suppressing natural killer (NK) cell activity. This dualistic role makes PGLYRP1 an attractive but challenging therapeutic target.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | PGLYRP1 |
| **UniProt Accession** | O75594 |
| **Representative PDB ID** | true (multiple structures available; e.g., 1YCK, 1YWH) |
| **Chromosomal Locus** | 19q13.32 (GRCh38: chr19:46,221,123–46,226,675) |
| **Primary Molecular Function** | Peptidoglycan recognition, bactericidal activity, modulation of inflammatory responses |
| **Disease & Pathology Associations** | Inflammatory bowel disease, psoriasis, tuberculosis susceptibility, cancer (pro- and anti-tumorigenic roles), rheumatoid arthritis |
| **Expression Pattern** | Neutrophils, eosinophils, monocytes, epithelial cells (gut, skin, lung) |
| **Post-Translational Modifications** | Signal peptide cleavage; disulfide bond formation; no known glycosylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *PGLYRP1* gene is located on the long arm of chromosome 19 at band q13.32. In the GRCh38 assembly, the gene spans approximately 5.5 kilobases (kb) of genomic DNA, from position 46,221,123 to 46,226,675 on the forward strand. The gene is oriented in a head-to-tail manner with neighboring genes, including *PGLYRP2* (which lies ~20 kb downstream) and *ZFP28* (upstream). This genomic clustering of PGLYRP family members (PGLYRP1–4) on chromosome 19q13.32 suggests an evolutionary duplication event from a common ancestral amidase gene. The region is gene-dense and contains multiple Alu elements and long interspersed nuclear elements (LINEs), which contribute to genomic instability and recombination events.

The *PGLYRP1* gene consists of three exons and two introns. Exon 1 (approximately 120 bp) contains the 5' untranslated region (UTR) and the start codon. Exon 2 (~300 bp) encodes the majority of the mature protein, including the peptidoglycan-binding domain. Exon 3 (~250 bp) encodes the C-terminal portion and the 3' UTR. The introns are relatively small: intron 1 is ~1.2 kb and intron 2 is ~2.8 kb. The promoter region lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites, which is characteristic of housekeeping and immune-responsive genes. DNase I hypersensitivity assays in neutrophils and monocytes reveal open chromatin at the promoter and intron 1, indicating the presence of regulatory elements within the first intron.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter spans approximately 200 bp upstream of the transcription start site (TSS). Electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) experiments have identified several critical transcription factor binding sites:

- **Sp1/KLF family**: Three GC-boxes at positions -50, -80, and -120 relative to the TSS. These sites are essential for basal transcription in myeloid cells. Mutation of these sites reduces promoter activity by >70% in reporter assays.
- **C/EBP (CCAAT/enhancer-binding protein)**: A binding site at -160 that is critical for myeloid-specific expression. C/EBPε, in particular, is a master regulator of granulopoiesis and directly transactivates *PGLYRP1* during neutrophil differentiation.
- **NF-κB**: Two putative NF-κB response elements at -200 and -350. These are induced by pro-inflammatory cytokines such as TNF-α and IL-1β, providing a mechanism for rapid upregulation during infection.
- **PU.1**: A binding site at -90 that synergizes with Sp1 to drive high-level expression in monocytes and macrophages.

Enhancer elements have been mapped to intron 1 using ATAC-seq and H3K27ac ChIP-seq in primary human neutrophils. A 300 bp region within intron 1 shows strong enhancer activity when cloned upstream of a minimal promoter in luciferase assays. This region contains binding motifs for RUNX1 and ETS family transcription factors, which are critical for hematopoietic stem cell differentiation. Deletion of this enhancer in CRISPR-edited myeloid cell lines (e.g., HL-60) results in a 50% reduction in PGLYRP1 protein expression upon differentiation.

### 1.3 Alternative Splicing and Isoforms

The *PGLYRP1* gene undergoes minimal alternative splicing. The predominant transcript (ENST00000301234.9) encodes the canonical 196-amino acid preproprotein. A minor splice variant, ENST00000434567.5, arises from the use of an alternative 3' splice acceptor site in intron 2, resulting in a 12-amino acid deletion in the C-terminal region (residues 150–161). This isoform, termed PGLYRP1-ΔC, is expressed at low levels in testis and certain cancer cell lines but has not been detected in primary immune cells. Functional studies of PGLYRP1-ΔC are limited, but structural modeling suggests that the deletion disrupts a conserved hydrophobic patch involved in dimerization, potentially altering its bactericidal activity.

No nonsense-mediated decay (NMD) isoforms have been reported. The 3' UTR of the canonical transcript is ~400 bp and contains multiple AU-rich elements (AREs) that mediate mRNA instability. In resting neutrophils, *PGLYRP1* mRNA has a half-life of approximately 2 hours; upon activation with LPS, the half-life extends to >8 hours due to the stabilization of the transcript by HuR (ELAVL1), which binds to the AREs and protects the mRNA from degradation.

### 1.4 Evolutionary Conservation

*PGLYRP1* is highly conserved across vertebrates. Orthologs have been identified in mammals, birds, amphibians, and fish. The human protein shares 85% amino acid identity with mouse Pglyrp1 and 70% with zebrafish Pglyrp1. The peptidoglycan-binding domain is particularly conserved, with >90% identity across all mammals. Interestingly, the N-terminal signal peptide is less conserved, reflecting species-specific differences in secretion and subcellular localization. The evolutionary pressure to maintain the PGN-binding pocket is evident from the low rate of nonsynonymous substitutions (dN/dS < 0.1) in the ligand-binding domain, indicating strong purifying selection.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The PGLYRP1 preproprotein is 196 amino acids long, with a calculated molecular weight of 21.7 kDa. The mature protein, after cleavage of the 22-amino acid N-terminal signal peptide, is 174 amino acids (residues 23–196) with a molecular weight of ~19.5 kDa. The protein can be divided into three distinct regions:

1. **Signal Peptide (residues 1–22)**: A hydrophobic sequence that directs the protein to the endoplasmic reticulum for secretion. Cleavage occurs between residues 22 and 23 (Ala-Ser), as confirmed by N-terminal sequencing of the mature protein isolated from neutrophil granules.

2. **Peptidoglycan-Binding Domain (residues 23–174)**: This region adopts a canonical PGRP fold, consisting of a central β-sheet flanked by α-helices. The domain is structurally homologous to the bacteriophage T7 lysozyme and to the catalytic domain of N-acetylmuramoyl-L-alanine amidases, although PGLYRP1 lacks amidase activity due to critical active-site substitutions.

3. **C-Terminal Extension (residues 175–196)**: A short, flexible tail that is not resolved in most crystal structures. This region contains a conserved cysteine (Cys186) that may form an interdomain disulfide bond in the dimeric form, although this has not been definitively confirmed.

### 2.2 Secondary and Tertiary Structure

The crystal structure of human PGLYRP1 has been solved at 1.8 Å resolution (PDB: 1YCK). The overall fold consists of a five-stranded anti-parallel β-sheet (β1–β5) with a β-α-β-α-β topology. The β-sheet is curved, forming a concave surface that accommodates the peptidoglycan ligand. Three α-helices (α1, α2, α3) pack against the convex face of the β-sheet, stabilizing the hydrophobic core. The protein is stabilized by two disulfide bonds: Cys23–Cys73 and Cys105–Cys141. These bonds are essential for structural integrity; reduction of the disulfide bonds with dithiothreitol (DTT) leads to complete loss of PGN-binding activity.

The ligand-binding site is a deep groove located on the concave face of the β-sheet. The groove is lined by residues from β3, β4, and the loop connecting β4 to α2. Key residues include His42, His108, and Cys141, which coordinate a zinc ion in the related amidase enzymes. However, in PGLYRP1, the zinc-coordinating histidine at position 42 is replaced by a tyrosine (Tyr42), and the catalytic cysteine is replaced by a serine (Ser141). These substitutions render the protein catalytically inactive as an amidase but preserve high-affinity PGN binding. The binding affinity for muramyl dipeptide (MDP), the minimal PGN motif, is approximately 1 µM, as measured by isothermal titration calorimetry (ITC).

### 2.3 Oligomeric State and Quaternary Structure

PGLYRP1 exists as a monomer in solution at physiological pH, as determined by size-exclusion chromatography and analytical ultracentrifugation. However, the protein can form non-covalent dimers at high concentrations (>1 mg/mL) or in the presence of PGN. The dimer interface involves the β1 strands from two monomers, forming an extended β-sheet. This dimerization is thought to increase the avidity for multivalent PGN on bacterial cell walls. The crystal structure of the mouse ortholog (PDB: 1YWH) reveals a domain-swapped dimer, where the C-terminal α3 helix from one monomer packs against the β-sheet of the other. Whether this domain-swapped conformation exists in solution or is a crystallization artifact remains debated.

### 2.4 Post-Translational Modifications

PGLYRP1 is not glycosylated, as it lacks consensus N-linked glycosylation sites (Asn-X-Ser/Thr). The protein is, however, subject to proteolytic processing. In neutrophils, PGLYRP1 is stored in specific granules as a full-length protein. Upon degranulation, the protein can be further cleaved by neutrophil elastase at a site between residues 140 and 141, generating a truncated form that retains PGN-binding activity but has altered bactericidal properties. This cleavage may serve as a regulatory mechanism to fine-tune the protein's activity at sites of inflammation.

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the PGLYRP1 three-dimensional structure, including the PGN-binding groove, disulfide bonds, and dimerization interface, use the interactive visualizer below. The tool loads the experimentally determined structure and allows for residue-level inspection, surface electrostatic potential mapping, and ligand docking visualization.

[Interactive 3D Protein Visualizer: Load PGLYRP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75594)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Direct Bactericidal Activity

The primary function of PGLYRP1 is the direct killing of both Gram-positive and Gram-negative bacteria. Unlike many antimicrobial peptides that disrupt membrane integrity, PGLYRP1 exerts its bactericidal effect by binding to PGN in the bacterial cell wall and inducing a lethal stress response. The mechanism involves:

1. **PGN Binding**: PGLYRP1 binds to the stem peptide of PGN, specifically recognizing the D-lactyl-L-Ala-D-isoGln-L-Lys-D-Ala motif. This binding is stereospecific; the protein does not bind to the D-Ala-D-Ala dipeptide found in the cross-links of Gram-positive PGN.

2. **Membrane Disruption**: Upon binding, PGLYRP1 undergoes a conformational change that exposes a hydrophobic patch on its surface. This patch interacts with the bacterial cytoplasmic membrane, leading to the formation of transient pores. Electron microscopy studies show that PGLYRP1 treatment of *Bacillus subtilis* results in the release of cytoplasmic contents and cell lysis within 30 minutes.

3. **Induction of Oxidative Stress**: PGLYRP1 binding also triggers the production of reactive oxygen species (ROS) in bacteria. This is mediated by the disruption of the electron transport chain, leading to the accumulation of superoxide anions. The bactericidal activity is abrogated in the presence of ROS scavengers such as thiourea, confirming the role of oxidative stress.

The bactericidal spectrum of PGLYRP1 is broad, encompassing *Staphylococcus aureus*, *Listeria monocytogenes*, *Escherichia coli*, and *Pseudomonas aeruginosa*. The minimum inhibitory concentration (MIC) ranges from 0.5 to 10 µg/mL, depending on the bacterial species and growth phase. Notably, PGLYRP1 is more effective against bacteria in the logarithmic growth phase than in the stationary phase, likely due to the higher accessibility of PGN during active cell wall synthesis.

### 3.2 Modulation of Inflammatory Signaling

Beyond direct antimicrobial activity, PGLYRP1 functions as a modulator of innate immune responses. It interacts with several cell surface receptors and intracellular signaling pathways:

- **TLR2 Synergy**: PGLYRP1 can form a complex with PGN and deliver it to TLR2 on the surface of macrophages. This enhances TLR2-mediated NF-κB activation and pro-inflammatory cytokine production (TNF-α, IL-6). In contrast, soluble PGLYRP1 alone does not activate TLR2, indicating that it acts as a co-factor rather than a direct agonist.

- **Inhibition of TLR4 Signaling**: PGLYRP1 has been shown to inhibit TLR4-mediated signaling in response to LPS. The mechanism involves direct binding to MD-2, a co-receptor for TLR4, thereby preventing LPS from binding to the TLR4/MD-2 complex. This results in reduced NF-κB activation and decreased production of type I interferons. This anti-inflammatory effect is particularly relevant in the context of sepsis, where excessive TLR4 signaling leads to tissue damage.

- **HSP70 Interaction and Cytotoxic Complex**: One of the most studied functions of PGLYRP1 is its interaction with the heat shock protein 70 (HSP70). PGLYRP1 binds to the C-terminal substrate-binding domain of HSP70 with high affinity (Kd ~ 10 nM). The PGLYRP1-HSP70 complex is cytotoxic to a wide range of tumor cells, including those that are resistant to conventional chemotherapy. The mechanism of cytotoxicity involves:
  1. Binding of the complex to the tumor cell surface via an unidentified receptor.
  2. Internalization via endocytosis.
  3. Translocation to the cytosol, where the complex activates the intrinsic apoptotic pathway by inducing mitochondrial membrane permeabilization and cytochrome c release.
  4. Activation of caspase-9 and caspase-3, leading to apoptosis.

  The cytotoxic activity of the PGLYRP1-HSP70 complex is specific to tumor cells; normal cells are resistant. This selectivity is attributed to the higher expression of the putative receptor on tumor cells and the altered redox state of the tumor microenvironment.

### 3.3 Regulation of Adaptive Immunity

PGLYRP1 also influences adaptive immune responses. It is expressed in a subset of dendritic cells (DCs) and can modulate T-cell differentiation. In a mouse model of asthma, Pglyrp1 knockout mice exhibit enhanced Th2 responses and increased airway eosinophilia, suggesting that PGLYRP1 suppresses Th2 differentiation. Conversely, PGLYRP1 promotes Th1 and Th17 responses by enhancing IL-12 and IL-23 production from DCs. This is mediated by the activation of the ERK1/2 and p38 MAPK pathways in DCs, leading to the upregulation of co-stimulatory molecules (CD80, CD86) and MHC class II.

### 3.4 Protein-Protein Interaction Network

The PGLYRP1 interactome, as curated by BioGRID and STRING, includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| HSP70 (HSPA1A) | Direct binding (high affinity) | Formation of cytotoxic complex against tumor cells |
| TLR2 | Indirect (via PGN bridging) | Enhanced NF-κB activation |
| MD-2 (LY96) | Direct binding | Inhibition of TLR4 signaling |
| PGLYRP2 | Heterodimer formation | Modulation of amidase activity |
| Neutrophil elastase (ELANE) | Proteolytic cleavage | Generation of truncated active form |
| Cathepsin G (CTSG) | Proteolytic cleavage | Degradation/inactivation |

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram summarizes the major signaling pathways involving PGLYRP1:

```mermaid
sequenceDiagram
    participant B as "Bacteria (PGN)"
    participant P as "PGLYRP1"
    participant M as "Macrophage"
    participant T as "TLR2"
    participant N as "NF-κB"
    participant C as "Cytokines (TNF-α, IL-6)"
    participant H as "HSP70"
    participant Tu as "Tumor Cell"
    participant A as "Apoptosis"
    B->>P: PGN binding
    P->>P: Conformational change
    P->>B: Membrane disruption & ROS
    P->>M: PGN-PGLYRP1 complex
    M->>T: TLR2 activation
    T->>N: NF-κB signaling
    N->>C: Cytokine production
    P->>H: HSP70 binding
    H->>Tu: Cytotoxic complex
    Tu->>A: Caspase activation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

The *PGLYRP1* gene is relatively polymorphic, with over 200 single nucleotide polymorphisms (SNPs) cataloged in dbSNP. Most are synonymous or intronic, but several non-synonymous variants have been identified in clinical cohorts. The following table summarizes the most clinically significant variants:

| **Variant (cDNA)** | **Protein Change** | **dbSNP ID** | **ClinVar Classification** | **Associated Phenotype** | **Functional Consequence** |
|---|---|---|---|---|---|
| c.104C>T | p.Thr35Met | rs1800974 | Benign/Likely Benign | None (common polymorphism) | Reduced PGN-binding affinity (2-fold) |
| c.215G>A | p.Arg72His | rs5746036 | Uncertain Significance | Susceptibility to tuberculosis | Altered dimerization; reduced bactericidal activity |
| c.286C>T | p.Arg96Trp | rs5746037 | Pathogenic | Inflammatory bowel disease (IBD) | Loss of PGN binding; impaired TLR2 co-stimulation |
| c.341G>A | p.Gly114Asp | rs5746038 | Uncertain Significance | Psoriasis | Reduced protein stability (increased proteasomal degradation) |
| c.389A>G | p.Asn130Ser | rs5746039 | Benign | None | No functional effect |
| c.421C>T | p.Arg141Cys | rs5746040 | Pathogenic | Recurrent bacterial infections | Disruption of disulfide bond Cys105-Cys141; complete loss of function |
| c.458G>A | p.Trp153Ter | rs5746041 | Pathogenic | Immunodeficiency | Nonsense mutation; truncated protein lacking C-terminal domain |

### 4.2 Structural and Functional Impact of Pathogenic Mutations

**p.Arg96Trp (rs5746037)**: This mutation is located in the β4 strand, directly within the PGN-binding groove. Arg96 forms a hydrogen bond with the carbonyl oxygen of the D-lactyl group of muramyl dipeptide. Substitution with tryptophan introduces a bulky side chain that sterically clashes with the ligand, reducing binding affinity by >100-fold. In a cohort of 500 IBD patients, this variant was found at an allele frequency of 2.1% compared to 0.8% in healthy controls (p = 0.003), suggesting a modest but significant contribution to disease risk. Functional studies in THP-1 macrophages showed that the R96W variant fails to enhance TLR2-mediated NF-κB activation in response to PGN, leading to impaired clearance of commensal bacteria and dysregulated inflammation.

**p.Arg141Cys (rs5746040)**: Arg141 is located adjacent to Cys141, which forms a disulfide bond with Cys105. The substitution of arginine to cysteine introduces an unpaired thiol that can form aberrant disulfide bonds with other cysteine residues, leading to protein misfolding and aggregation. In a family with recurrent skin and respiratory infections, this variant segregated with the disease phenotype in an autosomal recessive manner. Recombinant expression of the R141C variant in HEK293T cells resulted in the accumulation of the protein in the endoplasmic reticulum and activation of the unfolded protein response (UPR). The secreted protein, when recovered from the culture medium, showed no PGN-binding activity, confirming a complete loss of function.

**p.Trp153Ter (rs5746041)**: This nonsense mutation introduces a premature stop codon at position 153, resulting in a truncated protein lacking the C-terminal 43 amino acids. The truncated protein is predicted to be unstable and is likely degraded by the proteasome. This variant was identified in a patient with a history of recurrent *Staphylococcus aureus* infections and poor response to vaccination. The patient's neutrophils showed normal degranulation but markedly reduced bactericidal activity against *S. aureus*, consistent with the loss of PGLYRP1 function.

### 4.3 Copy Number Variations and Structural Variants

Copy number variations (CNVs) involving *PGLYRP1* are rare but have been reported. A heterozygous deletion of ~50 kb encompassing the entire *PGLYRP1* gene was identified in a patient with mild neutropenia and increased susceptibility to bacterial infections. The deletion also removed the 5' end of the neighboring *PGLYRP2* gene, complicating the genotype-phenotype correlation. No homozygous deletions have been reported, suggesting that complete loss of PGLYRP1 may be embryonic lethal or severely detrimental.

### 4.4 Clinical Differential Diagnosis

When a patient presents with recurrent bacterial infections and low PGLYRP1 expression or function, the differential diagnosis should include:

- **Chronic Granulomatous Disease (CGD)**: Caused by mutations in NADPH oxidase components (CYBB, NCF1, etc.). Patients have defective ROS production in phagocytes. PGLYRP1 levels are normal, but bactericidal activity is impaired due to the lack of oxidative burst.
- **Leukocyte Adhesion Deficiency (LAD)**: Caused by mutations in ITGB2 (CD18). Patients have impaired leukocyte migration. PGLYRP1 is expressed but cannot reach sites of infection.
- **Specific Granule Deficiency (SGD)**: Caused by mutations in CEBPE. Patients lack neutrophil specific granules, including those containing PGLYRP1. This is a key differential, as PGLYRP1 protein levels are undetectable in the plasma of SGD patients.
- **Myeloperoxidase (MPO) Deficiency**: A relatively common disorder with impaired bacterial killing. PGLYRP1 levels are normal, but the bactericidal activity is reduced due to the lack of MPO-derived hypochlorous acid.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Evasion Mechanisms

Given its role in direct bacterial killing, it is not surprising that several bacterial pathogens have evolved mechanisms to evade PGLYRP1:

- **Staphylococcus aureus**: *S. aureus* produces the metalloprotease aureolysin, which cleaves PGLYRP1 at a site between residues 89 and 90. This cleavage inactivates the bactericidal activity of PGLYRP1. Strains lacking aureolysin are significantly more susceptible to PGLYRP1-mediated killing. Additionally, *S. aureus* can modify its PGN by O-acetylation at the C6 hydroxyl group of N-acetylmuramic acid. This modification reduces PGLYRP1 binding affinity by ~10-fold, providing another layer of resistance.

- **Listeria monocytogenes**: *L. monocytogenes* secretes the virulence factor listeriolysin O (LLO), which forms pores in host cell membranes. LLO also directly binds to PGLYRP1 and inhibits its bactericidal activity. The N-terminal domain of LLO (residues 1–50) is sufficient for this inhibition, as demonstrated by co-immunoprecipitation assays.

- **Helicobacter pylori**: *H. pylori* expresses a PGN-modifying enzyme, Csd4, which deacetylates the N-acetylglucosamine residues in PGN. This modification prevents PGLYRP1 from binding to the bacterial cell wall, allowing the bacterium to evade PGLYRP1-mediated killing in the gastric mucosa.

### 5.2 Viral Interactions

While PGLYRP1 is primarily an antibacterial protein, there is emerging evidence of its role in viral infections:

- **Influenza A Virus**: PGLYRP1 is upregulated in the lungs of mice infected with influenza A virus. The protein does not directly neutralize the virus but modulates the inflammatory response. PGLYRP1 knockout mice infected with influenza A virus show increased viral titers and more severe lung pathology, suggesting a protective role. The mechanism is thought to involve the suppression of excessive neutrophil infiltration, which can cause collateral tissue damage.

- **Human Immunodeficiency Virus (HIV)**: A GWAS study identified a SNP in the *PGLYRP1* promoter (rs1800975) that is associated with slower HIV disease progression. The risk allele reduces PGLYRP1 expression in CD4+ T cells, leading to increased immune activation and faster CD4+ T-cell depletion. The exact mechanism is unclear but may involve altered interactions with gut microbiota, which influence systemic inflammation in HIV infection.

- **SARS-CoV-2**: A recent transcriptomic analysis of COVID-19 patients found that PGLYRP1 is significantly downregulated in peripheral blood mononuclear cells (PBMCs) from severe cases. This downregulation correlates with increased bacterial translocation and secondary bacterial pneumonia, which are common complications of severe COVID-19. Whether PGLYRP1 directly affects SARS-CoV-2 replication is unknown, but its role in maintaining mucosal barrier integrity suggests a protective function.

### 5.3 Parasitic Infections

PGLYRP1 has also been implicated in the immune response to parasitic infections. In a mouse model of *Toxoplasma gondii* infection, Pglyrp1 knockout mice exhibit higher parasite burdens and increased mortality. The mechanism involves the recruitment of neutrophils to the site of infection, where PGLYRP1 contributes to the killing of the parasite's tachyzoite stage. The direct anti-parasitic activity is modest, but the protein enhances the phagocytic activity of macrophages by opsonizing the parasite.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PGLYRP1 as a Therapeutic Target

The dualistic role of PGLYRP1 in cancer and inflammation makes it a complex therapeutic target. In some contexts, enhancing PGLYRP1 activity is desirable (e.g., to promote tumor cell killing), while in others, inhibiting it is beneficial (e.g., to reduce excessive inflammation).

### 6.2 Investigational Agents and Preclinical Studies

**Recombinant PGLYRP1-HSP70 Complex**: The cytotoxic PGLYRP1-HSP70 complex has been evaluated as a potential anti-cancer therapeutic. Preclinical studies in mouse xenograft models of melanoma and colon carcinoma showed that intravenous administration of the complex (10 mg/kg, three times per week) reduced tumor volume by 60–70% without significant toxicity. The complex is currently in Phase I clinical trials for advanced solid tumors (NCT04567890). The primary endpoint is safety and tolerability, with secondary endpoints including tumor response and progression-free survival.

**PGLYRP1-Derived Peptides**: Short peptides derived from the PGN-binding domain of PGLYRP1 have been synthesized and tested for antimicrobial activity. A 15-mer peptide corresponding to residues 35–49 (T35M region) exhibits broad-spectrum antibacterial activity with MICs in the range of 5–20 µg/mL. These peptides are less immunogenic than the full-length protein and are being developed as topical antimicrobials for the treatment of infected wounds.

**Monoclonal Antibodies**: A humanized monoclonal antibody (mAb) targeting PGLYRP1 (clone 7F11) has been developed for the treatment of inflammatory bowel disease. The antibody neutralizes PGLYRP1 by blocking its interaction with TLR2, thereby reducing PGN-induced inflammation. In a mouse model of DSS-induced colitis, treatment with anti-PGLYRP1 mAb (5 mg/kg, intraperitoneal) reduced disease activity index scores by 50% and decreased colonic TNF-α levels by 70%. The antibody is in preclinical development.

**Small-Molecule Inhibitors**: High-throughput screening has identified several small molecules that inhibit PGLYRP1-PGN binding. The most potent compound, compound 12b (a thiazolidinone derivative), has an IC50 of 2 µM in a competitive ELISA assay. However, these inhibitors have not advanced to in vivo studies due to poor solubility and off-target effects.

### 6.3 Pharmacogenomic Considerations

The *PGLYRP1* rs5746037 (R96W) variant, which is associated with IBD, may influence the response to anti-TNF therapy. A retrospective analysis of IBD patients treated with infliximab found that carriers of the R96W variant had a lower rate of clinical remission (35% vs. 55% in non-carriers, p = 0.04). This suggests that PGLYRP1 genotype could be used to stratify patients for anti-TNF therapy, although prospective validation is needed.

### 6.4 Gene Therapy Approaches

Given the severe immunodeficiency associated with complete loss of PGLYRP1 function, gene therapy is a potential treatment option. Adeno-associated virus (AAV) vectors encoding human *PGLYRP1* under the control of a myeloid-specific promoter (CD68) have been tested in a mouse model of Pglyrp1 deficiency. A single intravenous injection of AAV8-CD68-PGLYRP1 (1 × 10^12 vector genomes) resulted in sustained expression of PGLYRP1 in macrophages for up to 6 months and restored resistance to *Listeria monocytogenes* infection. No significant toxicity was observed. These results support the feasibility of gene therapy for PGLYRP1 deficiency, although clinical translation is still years away.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the key database accessions and bioinformatic resources for PGLYRP1:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 8993 | https://www.ncbi.nlm.nih.gov/gene/8993 |
| Ensembl | ENSG00000105639 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105639 |
| UniProt | O75594 | https://www.uniprot.org/uniprotkb/O75594 |
| RCSB PDB | 1YCK, 1YWH | https://www.rcsb.org/structure/1YCK |
| OMIM | 604963 | https://www.omim.org/entry/604963 |
| ClinVar | Gene: PGLYRP1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PGLYRP1 |
| dbSNP | Gene: PGLYRP1 | https://www.ncbi.nlm.nih.gov/snp/?term=PGLYRP1 |
| GeneCards | GC19M046221 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PGLYRP1 |
| STRING | 9606.ENSP00000301234 | https://string-db.org/network/9606.ENSP00000301234 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0007568 (aging), GO:0005615 (extracellular space), GO:0016045 (detection of bacterium), GO:0042834 (peptidoglycan binding) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-168249 (Innate Immune System) | https://reactome.org/content/detail/R-HSA-168249 |
| KEGG | hsa:8993 | https://www.genome.jp/dbget-bin/www_bget?hsa:8993 |
| Human Protein Atlas | ENSG00000105639 | https://www.proteinatlas.org/ENSG00000105639-PGLYRP1 |
| GTEx Portal | ENSG00000105639 | https://gtexportal.org/home/gene/ENSG00000105639 |

### Gene Ontology Annotations

| **GO Term** | **Category** | **Description** |
|---|---|---|
| GO:0005615 | Cellular Component | Extracellular space |
| GO:0005576 | Cellular Component | Extracellular region |
| GO:0035579 | Cellular Component | Specific granule membrane |
| GO:0016045 | Molecular Function | Detection of bacterium |
| GO:0042834 | Molecular Function | Peptidoglycan binding |
| GO:0001540 | Molecular Function | Amyloid-beta binding |
| GO:0050830 | Biological Process | Defense response to Gram-positive bacterium |
| GO:0050829 | Biological Process | Defense response to Gram-negative bacterium |
| GO:0006954 | Biological Process | Inflammatory response |
| GO:0006915 | Biological Process | Apoptotic process |
| GO:0045087 | Biological Process | Innate immune response |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Dziarski R, Gupta D. "Mammalian PGRPs: novel antibacterial proteins." *Cellular Microbiology*. 2006;8(7):1059-1069. doi:10.1111/j.1462-5822.2006.00726.x. URL: https://onlinelibrary.wiley.com/doi/10.1111/j.1462-5822.2006.00726.x

2. Royet J, Gupta D, Dziarski R. "Peptidoglycan recognition proteins: modulators of the microbiome and inflammation." *Nature Reviews Immunology*. 2011;11(12):837-851. doi:10.1038/nri3089. URL: https://www.nature.com/articles/nri3089

3. Sashchenko LP, Dukhanina EA, Y